Theralink Technologies Inc (THER)

[BooDog]

OncBioMune has received all necessary approvals from the host hospital, associated committees and the U.S. Food and Drug Administration to begin the Phase 2 trial. All requisite information has been submitted to clinicaltrials.gov, with the expectations that the summary of the trial will soon be available for public viewing.

https://www.otcmarkets.com/stock/OBMP/news/OncBioMune-Signs-Work-Order-for-Phase-2-Clinical-Trial-of-ProscaVax-for-Early-Stage-Prostate-Cancer?id=197023

As I've stated countless times here, yes, I did expect this to go through the FDA and see the protocol on the FDA website, as well as Harvard's.

I'm curious if there is some form of a financing/partnership deal in the works. Would like to see a solid financial base before too long. We need it.

Once the Harvard trial is posted for everyone to see, we just may get some more attention. And the Texas trial as well.


No no no...you guys didn't think that...You all said the FDA nod wasn't necessary for this Harvard trial...that the Review board was good enough. I argued that couldn't and shouldn't be the case...

Once again....

Posted by: BooDog
In reply to: learningcurve2020 who wrote msg# 5859 Date:6/26/2018 2:08:34 PM
Post #5861 of 6043


I have, maybe not a dozen times, but enough. All we have is what they put out in the last press release. I'm a very patient investor when it comes to start up bios. Especially struggling ones. I am also a fundamentalist, otherwise I wouldn't care about something as simple as a protocol #. Just remember who's clicking the buy/sell button. If they get the funding, we'll see the lights get much brighter. IMO. And really, both trials aren't that expensive.


A few of the posts. No big deal

Post #5858
Post #5769
Post #5624
Post #5440
Post #5377
Post #4603

This just goes to early June.

Posted by: BooDog
In reply to: learningcurve2020 who wrote msg# 5857 Date:6/26/2018 1:26:49 PM
Post #5858 of 6043


Think I've given this answer at least a dozen times. Yes, we are waiting to see the trial post here https://clinicaltrials.gov/ct2/results?cond=&term=oncbiomune&cntry=&state=&city=&dist= and then here as well... https://www.bidmc.org/centers-and-departments/cancer-center/cancer-center-programs-and-services/genitourinary-cancer-program/genitourinary-cancer-clinical-trials

What's missing is a protocol #. Which tells me it may have something to do with funding. A phase 2 trial not on the FDA site, even if results aren't posted after completion on the FDA website (often times they aren't) would be pointless to bio investors. We want to see the actual protocol and the clinics involved.

That's what I'm waiting to see.

$OBMP

I'll go a bit further back this time...

Posted by: BooDog
In reply to: megabandp who wrote msg# 4419 Date:5/16/2018 4:41:46 PM
Post #4423 of 6043


It's Harvard approved, not FDA approved. Actually the FDA gave the company the go ahead about a year ago once the phase 1 was completed and reviewed. Actually they were given the go ahead for a phase 1b but decided to go straight to phase 2. The phase 2 needed to get the protocol "approved" through Harvard Medical Center. Then all that was sent to the FDA. FDA simply reviews and if their are no red flags within a 30 day period the trial can start.

Just so we clear things up a bit. When we're ready to go to market, that's when we're FDA "Approved".

Hope this clears things up.

Keep an eye out here for the phase 2 trial to be posted...

https://clinicaltrials.gov/ct2/results?cond=&term=oncbiomune&cntry=&state=&city=&dist=



Cheers! Now bring on the momentum! And the filings!

Much more to come!

$OBMP

Message in reply to:

If this isn't FDA phase 2 then what is it? IRB is listed on FDA website. Regardless we are in much better position for Pfizer buyout.

May see the North Texas trial kick off near term as well!

==============================

Message in reply to:

No no no...you guys didn't think that...You all said the FDA nod wasn't necessary for this Harvard trial...that the Review board was good enough. I argued that couldn't and shouldn't be the case...


Anyway, good to see leadership get it right with FDA inclusion all the way!